LATEST NEWS
Rethinking the immunotherapy paradigm for a sustainable and equal cancer care
Dose optimisation of immune checkpoint inhibitors may help address current healthcare resource constraints and improve treatment access
Study supports radiomics in predicting immunotherapy effectiveness in advanced NSCLC
In a real-world study, multimodal artificial intelligence models outperform PD-L1 across key endpoints
Next-generation KRAS G12C inhibitor shows promising activity in advanced colorectal cancer
Manageable safety and encouraging antitumour responses were presented with MK-1084 monotherapy and combination regimens
AI & DIGITAL ONCOLOGY
The first ESMO guidance for AI-based biomarkers
In a newly released framework paper, ESMO defines criteria for assessing and implementing AI-based biomarkers in oncology
Harnessing Large Language Models in oncology: ESMO’s framework for integration in the clinic
The ELCAP statements, developed by a group of international experts, help oncology stakeholders recognise the opportunities and the risks of these artificial intelligence systems by categorising them into three types
AI model boosts survival prediction accuracy after neoadjuvant chemotherapy in breast cancer
A study compared the performance of different models using routinely collected clinicopathological data from women with HR-positive/HER2-negative breast cancer
2025 ONCOLOGY HIGHLIGHTS
Novel ADCs from Asia open new clinical opportunities
Phase I–II studies showcase the clinical potential of novel ADCs with enhanced targeting and/or payload strategies
177Lu-DOTATATE prolongs progression-free survival in previously treated advanced GEP-NETs
Impressive results from the Chinese LUMINET-1 phase III study confirm and extend previous findings in Western patients
Trastuzumab deruxtecan is moving to the curative setting in early HER2-positive breast cancer
Positive findings from the DESTINY-Breast05 and DESTINY-Breast11 trials suggest that a paradigm change in the treatment of high-risk patients may be imminent
OPINIONS
Sex and gender are key for precision oncology and benefit all patients
Berna Özdemir
The power of dual-layer genomics in precision oncology
Umberto Malapelle
Shaping the use of AI in oncology
Jakob N. Kather
Artificial intelligence is expediting the development of therapeutic immunotherapies
Sine Reker Hadrup
Going beyond protocol is key for young people with cancer
Eileen Poon
OPINIONS
Sex and gender are key for precision oncology and benefit all patients
Berna Özdemir
The power of dual-layer genomics in precision oncology
Umberto Malapelle
Shaping the use of AI in oncology
Jakob N. Kather
Artificial intelligence is expediting the development of therapeutic immunotherapies
Sine Reker Hadrup
Going beyond protocol is key for young people with cancer
Eileen Poon